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ABSTRACT 
Background: 
Although 18F-fluorodeoxyglucose (FDG) positron emission tomography combined with 
computed tomography (PET/CT) is a potentially powerful, non-invasive imaging tool in 
differentiating adrenal metastasis from benign disease, some adenomas also exhibit high FDG 
uptake, therefore mimicking metastasis (i.e. false positives). We aimed to evaluate the accuracy 
of FDG-PET/CT based exclusively on histology and to identify risk factors for adrenal 
metastasis. 
Methods: 
Among the 289 consecutive patients who underwent adrenalectomy, 39 (78.0%) patients had 
suspected solitary adrenal metastasis and had a positive preoperative FDG-PET/CT. The FDG-
PET/CT findings were correlated with the histology of the excised adrenal gland. To identify risk 
factors for adrenal metastasis, characteristics were compared between patients with 
histologically-proven adrenal metastasis and those without. Youden’s index was used to 
calculate the optimal cut-off value for predicting adrenal metastasis. 
Results: 
Histology of the excised adrenal tumor confirmed adrenal metastasis in 28/39 (71.8%) patients 
while non-metastatic lesions comprised mostly benign adrenal cortical adenoma (n=10) and one 
non-functional pheochromocytoma. Therefore, the overall false positive rate of FDG-PET/CT 
was 28.2%. History of primary lung malignancy (odds ratio (95%CI)= 20.00 (1.01 – 333.3), 
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p=0.049) and SUVmax >2.65 (odds ratio (95%CI)=31.606 (2.46 – 405.71), p=0.008) were 
independent risk factors for adrenal metastasis. 
Conclusions: 
Single adrenal uptake on FDG-PET/CT in suspected solitary adrenal metastasis was associated 
with a high false positive rate (28.2%). Risk factors associated with adrenal metastasis included a 
history of known primary lung malignancy and a SUVmax >2.65 at the adrenal lesion of interest 
on FDG-PET/CT. Based on these findings, a new algorithm was constructed.
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INTRODUCTION 
The adrenal gland is a common site for metastasis in patients with malignancy. It is estimated 
that up to 50% of all adrenal masses incidentally detected in patients with history of malignancy 
would harbor metastases1-3. Since adrenalectomy for solitary adrenal metastasis offers survival 
benefit in selected patients4-5, establishing whether these adrenal masses are in fact metastatic or 
not is clinically important. Radio-guided fine needle aspiration of these masses could provide 
definitive diagnosis of adrenal metastasis but is invasive and may be associated with significant 
morbidity and high inadequacy6-7.  
18F-fluorodeoxyglucose (FDG) positron emission tomography combined with computed 
tomography (PET/CT) is a relatively new, non-invasive tool that could help to characterize these 
adrenal masses. Several reports have shown the effectiveness of stand-alone FDG-PET/CT to 
differentiate benign from malignant adrenal lesions1,2,8. It works on the basis that malignant 
adrenal tissue (i.e. metastasis) tends to have a higher uptake of radio-labelled glucose analog 
(because of increased glycolysis) than benign or normal adrenal tissue. However, it is not perfect 
because although most benign adenomas have FDG uptake equal to or below liver (i.e. appearing 
as little to no uptake), some exhibit FDG uptake greater than the liver (i.e. increased uptake), 
therefore mimicking metastases. In fact, a recent study has found an unexpected high false 
positive rate (i.e. an adrenal lesion appearing positive on FDG-PET/CT but ending up benign on 
histology)9. Given that the vast majority of the current literature reporting the accuracy of FDG-
PET/CT is based on interval CT follow-up 1,2,10,11 instead of actual histology which should be 
regarded as the gold standard for determining the nature of an adrenal mass, the present study 
aimed to first evaluate the accuracy of FDG-PET/CT based exclusively on histology and 
secondly, to identify potential significant factors associated with adrenal metastasis.   
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PATIENTS AND METHODS 
All consecutive patients who underwent adrenalectomy at our institution by our team from 2001 
to 2013 were retrospectively reviewed. To be eligible for analysis, patients had to have a 
suspected solitary adrenal metastasis and undergone a preoperative FDG-PET/CT within 2 
months before adrenalectomy. Those with apparent oligometastatic disease on presentation were 
not included as they are expected to have a higher chance of adrenal metastasis. All patients 
underwent routine hormonal evaluations before adrenalectomy including overnight 1-mg 
dexamethasone test, 24-hour urinary catecholamines and a plasma aldosterone to renin ratio (if 
hypertensive)3 as well as a dedicated adrenal protocol CT performed with no contrast, 1-min 
post-contrast and 15-min delayed post contrast scans before FDG-PET/CT. All scans were 
reported by dedicated radiologists. The findings on the preoperative FDG-PET/CT were 
correlated with the final histology of the excised adrenal gland. During the study period, 
preoperative FDG-PET/CT was not mandatory for all patients with a suspected adrenal 
metastasis but was increasingly being performed for the purpose of cancer staging (i.e. excluding 
extra-adrenal metastatic diseases before adrenalectomy). Since the findings of the FDG-PET/CT 
was not intended to differentiate metastasis from benign disease, the decision for adrenalectomy 
was based on clinical suspicion of an adrenal metastasis. For the purpose of the study, clinical 
suspicion of an adrenal metastasis was categorized into 4 groups, namely a new lesion (i.e. an 
adrenal lesion not apparent from previous CT scans if available), a lesion with interval 
enlargement (which was defined as >20% increase in any one dimension over one year or by pro 
rata if duration was not exactly one year), a large lesion (i.e. ≥4.0cm in the largest dimension) 
and a lesion with indeterminate CT features (such as attenuation by Hounsfield unit > 10 on non-
contrast CT scan and / or absolute washout pattern > 60% or relative washout > 40% on contrast 
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CT scan)1,3. Characteristics such as age, sex, main reason for suspecting adrenal metastasis, type 
of primary non-adrenal malignancy, PET/CT findings and final adrenal pathology of the eligible 
patients were extracted from patient charts. 
FDG-PET/CT technique 
All patients were asked to fast for a minimum of 6 hours with serum glucose level confirmed to 
be < 120 mg/dL before intravenous administration of 370 to 555 MBq of FDG through a 
peripheral vein. After 60 minutes, FDG-PET/CT images were acquired using a full-ring 
dedicated PET scanner. Images were acquired from the base of skull to the mid-thigh. The 
maximum standardized uptake value (SUVmax) for the particular adrenal lesion of interest was 
recorded by drawing a rectangular three-dimensional region of interest around the nodule.  
To identify for potential risk factors associated with adrenal metastasis, preoperative patient 
baseline characteristics were compared between those with histologically proven adrenal 
metastasis (malignant group) and those without adrenal metastasis (benign group). 
Statistical analysis 
Statistical analysis was performed by chi-square or Fisher’s Exact test to compare categorical 
variables, and Mann-Whitney U test was used to compare continuous variables between groups. 
Variables significant in the univariate analysis (p<0.10) were entered into multivariate analysis. 
To improve clinical utility of significant continuous variables (such as SUVmax and tumor size), 
Youden’s index12 was used to calculate the best cut-off value for predicting adrenal metastasis. 
The AUC was used to measure the predictive accuracy. AUC values closer to 1 meant better 
predictability whereas values closer to 0.5 meant poorer predictability. A bootstrap approach 
with 1,000 resamples was used to estimate 95% confidence intervals for AUC and to compare 
two AUCs. All statistical analyses were conducted using SPSS version 18.0 (SPSS, Inc., Chicago, 
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IL, USA) and R version 2.14.0 (R Foundation for Statistical Computing, Vienna, Austria). 
P<0.05 was considered statistically significant. 
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RESULTS 
Altogether 289 consecutive patients underwent adrenalectomy. Of these, 50 (17.3%) were 
suspected solitary adrenal metastasis and 39 (78.0%) patients had a preoperative FDG-PET/CT 
within 2 months of adrenalectomy. All patients who underwent a preoperative FDG-PET/CT had 
a single positive adrenal uptake in the suspected lesion and all were tested negative for hormonal 
hyper-secretion. The patient baseline characteristics (such as age, sex, type of primary 
malignancy, suspicion and risk of metastasis) between those did (n=39) and those who did not 
undergo preoperative FDG-PET/CT (n=11) were not significantly different (data not shown).   
Table 1 shows the baseline characteristics of the 39 patients who underwent preoperative FDG-
PET/CT. All patients had a single FDG uptake in their respected adrenal lesion. The mean (±SD) 
SUVmax of the adrenal lesion was 5.5 ± 3.5 while the mean (±SD) size of adrenal lesion was 4.0 
± 2.3cm. The most common primary malignancy was non-small cell lung cancer (n=16, 41.0%) 
followed by lymphoma (n=4, 10.3%), esophagus/stomach (n=4, 10.3%), gynecological cancer 
(n=4, 10.3%), breast (n=2, 5.1%), pancreas (n=2, 5.1%), liver (n=2, 5.1%), colon (n=2, 5.1%), 
kidney (n=1, 2.6%), sarcoma (n=1, 2.6%) and nasopharyngeal cancer (n=1, 2.6%). Final 
pathology of the excised adrenal tumor confirmed adrenal metastasis in 28/39 (71.8%) patients 
while the pathology of the non-metastatic lesions were mostly benign adrenal cortical adenoma 
(n=10) with one pheochromocytoma (n=1). For this latter patient, the two sets of preoperative 
24-hour urinary collections for catecholamines were normal and there were no unexpected 
intraoperative hemodynamic changes during surgical dissection. Therefore, it was probably a 
non-functional pheochromocytoma. The SUVmax value in this patient was 7.80. Based on these 
findings, the true positive and false positive rates of FDG-PET/CT were 71.8% and 28.2%. The 
risk of adrenal metastasis based on the 4 suspicion categories alone (a newly-found lesion, 
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progressive size increase, size alone and indeterminate CT appearance) were 9/12 (75%), 11/15 
(73.3%), 4/7 (57.1%) and 4/5 (80.0%), respectively. 
Table 2 shows the clinical details of the 11 patients with false-positive FDG-PET/CT. 
Table 3 shows a comparison of preoperative baseline characteristics between the malignant 
(n=28) and benign group (n=11). Age, sex ratio, time period, clinical suspicion and side of 
adrenal lesion were not significantly different between the two groups. The malignant group 
tended more likely to have history of primary lung malignancy (50% vs. 18.2%, p=0.069), larger 
sized adrenal lesion (4.3 ± 2.4cm vs. 3.2 ± 2.0cm, p=0.079) than the benign group. The mean 
SUVmax value was significantly higher in the malignant group (6.4 ± 3.5 vs. 3.6 ± 1.9, p=0.005). 
Table 4 shows the multivariate analysis for adrenal metastasis. After adjusting for size of adrenal 
lesion, history of primary lung malignancy (ß coefficient= 2.476, odds ratio=11.905, 
95%CI=1.298 – 111.111, p=0.028) and SUVmax value (ß coefficient= 0.504, odds ratio=1.656, 
95%CI=1.086 – 2.524, p=0.019) were independent risk factors for adrenal metastasis. The 
optimal cut-off value in predicting adrenal metastasis for SUVmax was 2.65 (Youden’s index = 
0.532; sensitivity 89.3% and specificity 63.6%). In terms of overall predictability (as measured 
by AUC), SUVmax had an AUC value of 0.792 (95%CI=0.629 – 0.955). Although the AUC for 
SUVmax was higher (i.e. more predictive) in patients with a history of primary lung malignancy 
(n=16) than those with a history of primary non-lung malignancy (n=23), the two AUCs were 
not significantly different (0.893 vs. 0.810, p=0.521). 
Based on these findings, we proposed a clinical algorithm for incidentally found adrenal mass in 
patients with history of malignancy. Figure 1 shows the proposed algorithm. 
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DISCUSSION 
FDG-PET/CT has become increasingly popular for diagnosing solitary adrenal metastasis in 
patients with a history of primary non-adrenal malignancy. A large meta-analysis and systematic 
review of 21 studies found that the overall sensitivity and specificity of FDG-PET/CT in 
differentiating malignant and benign adrenal disease in patients with known primary malignancy 
were 97% and 91%, respectively2. In this particular report, the reported false positive rate was 
only 5.8% 2. However, the authors cautioned that in their study, the histological diagnosis for the 
majority of lesions was not available and the final diagnosis was based mostly on serial imaging 
(a widely accepted method among non-surgical series). We believe this might be one of the main 
reasons for the difference in false positive rate between most other studies and ours. Our study 
found that among patients with a single positive FDG uptake in the suspected adrenal metastasis, 
the chance of metastasis was only 71.8% and so the false positive rate was 28.2%. In other words, 
almost 1 in 3 positive on FDG-PET/CT turned out to be non-metastatic. Even if one excluded the 
non-functional pheochromocytoma (as this is a heterogeneous tumor with malignant potential), 
the false positive rate was still 10/38 or 26.3%. This false positive rate appeared even higher than 
that of a recent study that examined the accuracy of FDG-PET/CT based on histology9. 
Interestingly, when one looked at the chance of adrenal metastasis among the 4 clinical suspicion 
categories, the false positive rate for FDG-PET/CT was actually higher than having either a new 
adrenal lesion or an adrenal lesion with interval enlargement or “indeterminate” CT features 
(28.2% vs 25.0%, 26.7%, 20.0%, respectively). 
Apart from assessing the accuracy of FDG-PET/CT in differentiating malignant from benign 
adrenal disease, our study also identified two independent risk factors for adrenal metastasis. Our 
data found that the history of primary lung malignancy (odds ratio=11.91, 95%CI 1.30 – 111.1) 
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and SUVmax (odds ratio=1.66, 95%CI=1.09 – 2.52) were significant risk factors for adrenal 
metastasis. From our analysis, patients with primary lung malignancy had almost 11 times 
greater chance of harboring an adrenal metastasis than those with non-lung primary malignancy. 
This is consistent with the finding that lung primary malignancy is the most common malignancy 
metastasizing to the adrenals1-3,10-11. Using an optimal cut-off of 2.65, those with SUVmax >2.65 
had a 31.6 times greater chance of adrenal metastasis than those with SUVmax ≤2.65. Our data 
also showed that SUVmax was a significant factor and there appeared to be no significant 
difference in predictability (by AUC) (p=0.521) whether the patient had a history of lung or non-
lung primary malignancy. With this cut-off of 2.65, the sensitivity and specificity were 89.3% 
and 63.6%, respectively which appeared slightly less than previous studies. Metser et al. found 
that with a SUVmax cut-off of 3.10, the sensitivity and specificity were 98.5% and 92%, 
respectively13. Using the same cut-off, another study reported the sensitivity and specificity were 
91% and 81%, respectively14. However, determining SUVmax cut-off among different studies is 
difficult as it is dependent on many factors including body habitus and composition, timing of 
the radionuclide injection, plasma glucose concentration and partial volume effects2. Therefore, 
some have advocated the use of qualitative visual assessment alone as a criterion for determining 
malignancy on FDG-PET/CT2,11,14,15. 
Despite these findings, we would like to acknowledge that this was a retrospective review of a 
relatively small number of patients who had preoperative FDG-PET/CT and so some of the non-
significant findings might have been due to the lack of power of this study. Also although 
hormonal evaluations were performed for all patients, subtle or intermittent hyper-secretion from 
a benign adrenal adenoma could not be completely ruled out and may account for the high false 
positive rate16.  
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Conclusion 
Our data showed that a single positive adrenal uptake on FDG-PET/CT in patients with known 
malignancy was associated with an unexpected high rate of false positive (28.2%) and this rate 
was not significantly lower than normally-used clinical criteria such as having a new adrenal 
lesion or a lesion with interval enlargement or indeterminate CT features. Factors associated with 
adrenal metastasis included a history of known primary lung malignancy and a SUVmax >2.65 
at the adrenal lesion of interest. A new working algorithm was constructed.  
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Table 1. The baseline characteristics of the 39 patients with suspected single adrenal metastasis 
who underwent FDG-PET/CT scan before adrenalectomy  
Parameters  
Mean (± SD) age at operation (years) 57.9 ± 13.3 
Sex (Male/Female) 23 : 16 
History of primary malignancy 
 - Lung 
 - Lymphoma 
 - Esophagus/stomach 
 - Gynecological cancer 
 - Breast 
 - Pancreas 
 - Liver 
 - Colon 
 - Others 
 
16 (41.0) 
4 (10.3) 
4 (10.3) 
4 (10.3) 
2 (5.1) 
2 (5.1) 
2 (5.1) 
2 (5.1) 
3 (7.7) 
PET/CT findings or appearance 
- Right / Left  
- Discrete nodule / hyperplasia 
- Tumor size (cm) 
- CT attenuation (HU ≤ 10)  
- SUVmax 
 
15 (38.5) / 24 (61.5) 
36 (92.3) / 3 (7.7) 
4.0 ± 2.3 
33 (84.6%) 
5.5 ± 3.5 
Abbreviations: PET/CT = positron emission tomography/computed tomography; HU – 
Hounsfield Unit; SUVmax = maximum standardized uptake value  
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Table 2. Clinical details of the 11 patients with false-positive FDG-PET/CT (i.e. benign 
histology) 
Patient Clinical history Clinical suspicion / FDG-
PET/CT results 
Adrenal histology 
1 57-year-old male with a 
history of pancreatic cancer. 
New lesion / hypermetabolic 
left adrenal lesion 
(SUVmax=3.70) 
Adrenal cortical 
adenoma 
2 56-year-old male with a 
history of lung cancer 
Indeterminate CT washout 
pattern / hypermetabolic right 
adrenal lesion (SUVmax=2.90) 
Adrenal cortical 
adenoma 
3 28-year-old lady with a 
history of ovarian cancer 
New lesion / hypermetabolic 
left adrenal lesion 
(SUVmax=7.0) 
Adrenal cortical 
adenoma 
4 82-year old lady with a 
history of esophageal cancer 
Size>4cm / hypermetabolic left 
adrenal lesion (SUVmax=3.0) 
Adrenal cortical 
adenoma 
5 56-year-old lady with a 
history of lymphoma. 
Size>4cm / hypermetabolic left 
adrenal lesion (SUVmax=2.5) 
Adrenal cortical 
adenoma 
6 57-year-old male with a 
history of nasopharyngeal 
cancer.  
Progressive size increase / 
hypermetabolic left adrenal 
lesion (SUVmax=3.3) 
Adrenal cortical 
adenoma 
7 62-year-old lady with a 
history of lung cancer 
Progressive size increase / 
hypermetabolic right adrenal 
Adrenal cortical 
adenoma 
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lesion (SUVmax=2.2) 
8 43-year-old lady with a 
history of breast cancer 
Indeterminate washout pattern / 
hypermetabolic right adrenal 
lesion (SUVmax=2.5) 
Adrenal cortical 
adenoma 
9 73-year-old lady with a 
history of gastric cancer 
HU 34 on non-contrast CT / 
hypermetabolic left adrenal 
lesion (SUVmax=7.8) 
Non-functional 
pheochromocytoma 
10 72-year-old lady with a 
history of esophagus cancer 
Progressive size increase / 
hypermetabolic left adrenal 
lesion (SUVmax=2.9) 
Adrenal cortical 
adenoma 
11 55-year old lady with a 
history of breast cancer 
Progressive size increase / 
hypermetabolic right adrenal 
lesion (SUVmax=2.8) 
Adrenal cortical 
adenoma 
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Table 3. A comparison of preoperative clinical characteristics between those with histologically-
proven adrenal metastasis (i.e. malignant group) and those without (i.e. benign group) 
Parameters Benign group 
(n=11) 
Malignant group 
(n=28) 
p-value 
Age (±SD) at operation (years) 58.27 ± 14.68 57.78 ± 13.01 0.723 
Sex (male/female) 4 / 7 19 / 9 0.146 
Time period 
- 2001 – 2004 
- 2005 – 2009 
- 2010 – 2013  
 
2 (18.2) 
5 (45.5) 
4 (36.4) 
 
10 (35.7) 
12 (42.9) 
6 (21.4) 
0.475 
Main reason for suspecting adrenal metastasis 
- New lesion (not apparent in previous CT 
scan if available) 
- Interval enlargement (>20% over a year) 
- Lesion size ≥4cm 
- Indeterminate CT features* 
 
2 (18.2) 
 
4 (36.4) 
2 (18.2) 
3 (27.3) 
 
9 (32.1) 
 
11 (39.3) 
4 (14.3) 
4 (14.3) 
0.804 
0.693 
 
1.000 
0.379 
0.655 
Side of adrenal lesion 
- Right  
- Left 
 
4 (36.4) 
7 (63.6) 
 
11 (39.3) 
17 (60.7) 
0.694 
History of primary malignancy# 
- Lung 
- Non-lung 
 
2 (18.2) 
9 (81.8) 
 
14 (50.0) 
14 (50.0) 
0.069 
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PET/CT findings 
- Discrete nodule / hyperplasia 
- SUVmax# 
- Size of adrenal lesion (cm)# 
 
11 / 0 
3.61 ± 1.94 
3.2 ± 2.01 
 
25 / 3 
6.42 ± 3.47 
4.3 ± 2.39 
 
0.545 
0.005 
0.079 
Abbreviations: PET/CT = positron emission tomography/computed tomography; SUVmax = 
maximum standardized uptake value 
* including CT attenuation value > 10 Hounsfield unit and/ or absolute washout pattern > 60% or 
relative washout > 40%. 
# these factors were entered into the subsequent multivariate analysis for adrenal metastasis 
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Table 4. A multivariate analysis for adrenal metastasis 
Covariates Odds ratio 95% confidence 
interval 
p-value 
Primary lung malignancy 
- No 
- Yes 
 
1 
11.905 
 
 
1.298 – 111.111 
0.028 
SUVmax 1.656 1.086 – 2.524 0.019 
Size of adrenal mass 1.389 0.853 – 2.262 0.186 
SUVmax = maximum standardized uptake value 
When SUVmax was entered as a categorical variable using an optimal cut-off of 2.65, the odds 
ratio (95%CI) became 31.606 (2.462 – 405.714), p=0.008 while the odds ratio (95%CI) for 
primary lung malignancy became 20.00 (1.010 – 333.33), p=0.049. 
A proposed algorithm
An incidental adrenal mass in a 
patient with history of malignancy
Hormonal work-up
Is it new or has it increased in size 
over past 2 years?
Obtain non-contrast CT
Hounsfield unit ≥10
Obtain contrast CT (adrenal 
washout protocol) or MRI
Abnormal washout features or 
chemical shift on MRI
Hounsfield unit <10
Is the adrenal mass ≥4.0cm?
Yes
Benign adrenal 
mass, no follow-up 
needed
No
No abnormal CT 
washout features or 
chemical shift on MRI 
Obtain FDG-PET/CT scan
SUVmax ≥2.65 and / or history of 
primary lung malignancy
SUVmax <2.65 and history of 
primary non-lung malignancy
Surgical resection
Percutaneous biopsy
Malignant
Benign
Surgical resection
Yes
